What is Visceral Fat, and How Does It Affect Your Heart Health?
When undergoing a lipid panel, the focus is often on the levels of HDL and LDL cholesterol, commonly referred to as "good" and "bad" cholesterol. These measurements have traditionally been used to assess the risk of cardiovascular diseases. However, with advancements in medical research, our understanding has evolved. For instance, not all LDL cholesterol is "bad," and there are cases where individuals with normal lipid profiles still experience heart disease or stroke, highlighting the complexity of cardiovascular risk assessment.
When undergoing a lipid panel, the focus is often on the levels of HDL and LDL cholesterol, commonly referred to as "good" and "bad" cholesterol. These measurements have traditionally been used to assess the risk of cardiovascular diseases. However, with advancements in medical research, our understanding has evolved. For instance, not all LDL cholesterol is "bad," and there are cases where individuals with normal lipid profiles still experience heart disease or stroke, highlighting the complexity of cardiovascular risk assessment.
What is Advanced Lipid Profiling?
Advanced lipid profiling is a detailed analysis of LDL and HDL particles, as well as additional risk factors such as Lipoprotein (a) and inflammatory markers. This comprehensive assessment provides a deeper understanding of cardiovascular risk beyond standard cholesterol measurements.
-
Apolipoprotein B (ApoB): Apolipoprotein B (ApoB) is a protein-lipid complex primarily found in Low-Density Lipoprotein (LDL), as well as in Intermediate-Density Lipoprotein (IDL) and Very Low-Density Lipoprotein (VLDL). Each LDL particle contains one ApoB molecule, regardless of the size of the LDL particle. Research shows that higher ApoB levels are a stronger predictor of cardiovascular risk compared to traditional measures of LDL or cholesterol levels, even when LDL levels are within the normal range.
-
Small Dense LDL: Small dense LDL refers to smaller, more dense LDL particles. These particles have been shown to accumulate and trigger more inflammation in blood vessels compared to larger LDL particles. Small dense LDL levels are closely related to overall LDL levels, but they can become disproportionately high when triglyceride levels are elevated (e.g., above 80 mg/dL). As a result, it's possible to have a "normal" lipid profile while still having elevated small dense LDL levels, which may pose a higher cardiovascular risk.
-
Apolipoprotein A1 (ApoA1): Apolipoprotein A1 (ApoA1) is the primary protein found in High-Density Lipoprotein (HDL), with a one-to-one relationship to each HDL molecule. The ratio between ApoB and ApoA1 is an important additional marker for assessing cardiovascular risk, supported by evidence that it provides more accurate risk prediction than the traditional ratio of total cholesterol or non-HDL to HDL.
-
Lipoprotein(a) [Lp(a)]: Lipoprotein(a) [Lp(a)] is a particle similar to LDL but with a different protein structure. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular disease, including heart disease and stroke, even in individuals with otherwise normal LDL levels and good overall health. Lp(a) can contribute to vascular changes starting at a young age. Its levels are primarily determined by genetics, which is why it often runs in families. Current guidelines recommend a one-time measurement of Lp(a) for adults to assess residual cardiovascular risk, especially after managing factors like blood sugar, lipid levels, and body weight. If levels are normal, no further testing is needed.
-
High-Sensitivity C-Reactive Protein (hs-CRP): High-Sensitivity C-Reactive Protein (hs-CRP) is an inflammatory marker that has been linked to cardiovascular disease for over two decades. Recently, it has been recognized as an independent risk factor for cardiovascular conditions, regardless of other measurements. This reflects a growing understanding that chronic, low-grade inflammation plays a key role in disease development. Hs-CRP is also used to assess a process known as "inflammaging," which refers to the inflammation associated with aging.
As of current, VitalLife Health Promotion Center offers advanced testing and risk assessment for lipid-related diseases, including deep lipid profiling, genetic testing (genomics), and blood protein analysis (proteomics) to calculate personalized risk. These tests can be used alongside standard assessments such as coronary calcium scoring or carotid intima-media thickness (CIMT) ultrasound to provide a comprehensive evaluation of cardiovascular risk.
Click here to consult with our doctors for long-term health management with the Vital program, a one-year comprehensive health plan. This program provides in-depth health care, using advanced AI technology to analyze your health and detect potential issues at an early stage, before they develop into diseases. Additionally, it includes bi-annual measurements of various health markers related to disease risk. The program also integrates with the Bumrungrad Application to track your health data, helping you live a higher-quality life with VitalLife.